Seeing Is Believing
Currently out of the existing stock ratings of Joseph Stringer, 198 are a BUY (98.02%), 4 are a HOLD (1.98%).
Analyst Joseph Stringer, currently employed at NEEDHAM, carries an average stock price target met ratio of 27.29% that have a potential upside of 23.58% achieved within 107 days.
Joseph Stringer’s has documented 397 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on PHAT, Phathom Pharmaceuticals at 30-Aug-2024.
Analyst best performing recommendations are on RNA (AVIDITY BIOSCIENCES ).
The best stock recommendation documented was for RNA (AVIDITY BIOSCIENCES ) at 6/10/2024. The price target of $35 was fulfilled within 2 days with a profit of $7.89 (29.1%) receiving and performance score of 145.52.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
64
$25.1 (64.52%)
78
18 days ago
12/17 (70.59%)
$28.28 (79.17%)
382
Buy
85
$46.1 (118.51%)
85
22 days ago
10/16 (62.5%)
$47.99 (129.67%)
230
Buy
74
$35.1 (90.23%)
66
22 days ago
1/6 (16.67%)
$36.99 (99.95%)
24
Buy
83
$44.1 (113.37%)
85
22 days ago
5/8 (62.5%)
$45.99 (124.26%)
391
Hold
41
$2.1 (5.40%)
57
22 days ago
14/18 (77.78%)
$3.99 (10.78%)
125
Which stock is Joseph Stringer is most bullish on?
Which stock is Joseph Stringer is most reserved on?
What Year was the first public recommendation made by Joseph Stringer?